Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv Publisher Pubmed



Taki E1 ; Soleimani F2 ; Asadi A3, 4 ; Ghahramanpour H5 ; Namvar A6 ; Heidary M7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Chemistry, Medicinal Chemistry Research Laboratory, Shiraz University of Technology, Shiraz, Iran
  3. 3. Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Microbial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  6. 6. Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran
  7. 7. Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran
  8. 8. Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

Source: Expert Review of Anti-Infective Therapy Published:2022


Abstract

Introduction: The development of long-acting (LA) drugs has changed the management of common medical conditions for human replication immunodeficiency virus (HIV). Cabenuva (cabotegravir/Rilpivirine) is the first LA antiretroviral injectable drug composed of nano-formulation of cabotegravir (CAB) and rilpivirine (RPV). Areas covered: In this review article, we aim to have a brief overview of results of major clinical trials that administrated Cabotegravir/Rilpivirine for patients considering the efficacy and safety profiles. Moreover, we discuss about CAB and RPV chemical structure, mechanism of action, ‎activity against drug-sensitive and -resistant HIV, and pharmacodynamics/pharmacokinetics properties. Expert opinion: Based on the results of the ATLAS and FLAIR trials, Cabotegravir/Rilpivirine regimen once-monthly has shown equal effectivity to oral combination antiretroviral therapy (cART) in maintaining HIV-1 suppression in patients. Furthermore, ATLAS-2 M study revealed the non-inferiority of Cabotegravir/Rilpivirine regimen every 8 weeks compared to every 4 weeks. The injectable LA ART reduces the number of treatment intake as well as increases adherence, especially in patients with HIV-related stigma. Administration of extended-release agents probably minimize the risk of treatment-related toxicity and resistance related to sub-optimal adherence to oral ART, so Cabotegravir/Rilpivirine can be suggested as a suitable alternative for HIV infection control in current era. © 2022 Informa UK Limited, trading as Taylor & Francis Group.